All In Biotech

Drug Trial Radar · NCT03982134

PDR001 + Panobinostat for Melanoma and NSCLC

Phase Ib Study to Assess Safety and Tolerability of PDR001 in Combination With Panobinostat in Metastatic Melanoma and Non-small Cell Lung Cancer After Failure of Prior Anti PD1 or PD-L1 Therapy

Last checked: Nov 19, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Sep 2019

Primary completion

May 1, 2021

Study completion May 1, 2022

Sponsor

Lead sponsor
Muhammad FurqanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis Pharmaceuticals
First posted
Jun 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to find the dose of the study drug PDR001 that, when given in combination with the drug Panobinostat, results in the best outcomes for metastatic melanoma and non-small cell lung cancer (NSCLC)

Conditions

  • Melanoma
  • Non Small Cell Lung Cancer

Interventions

  • PDR001Drug

    PDR001 is a humanized IgG4 antibody

  • PanobinostatDrug

    Panobinostat is a Histone deacetylase inhibitor (HDACi).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of PDR001 in combination with panobinostat in determining a recommended Phase II doseTime frame: Initiation of treatment up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.